Anika Therapeutics ANIK Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -9.8%+43.3pp | -9.9%+36.6pp | -40.2%+19.2pp | -65.1%-20.6pp | -53.1%-7.7pp | |
| Returns | ||||||
| Return on equity | -8%+23.8pp | -7.5%+23.3pp | -20.2%+23.1pp | -33.9%-3.2pp | -31.8%-0.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.2× | 0.6×+0.1× | 0.4×-0.2× | 0.4×-0.2× | 0.5×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4.5×-1.3× | 4.7×-0.2× | 5.3×0.0× | 6.2×+0.2× | 5.7×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | |
| Valuation | ||||||
| Market capitalization | $204.37M+31.6% | $138.59M-42.5% | $135.53M-62.9% | $161.05M-56.4% | $213.07M-43.5% | |
| Price / sales | 1.8×+0.1× | 1.2×-0.8× | 1.6×-0.6× | 1.7×-0.5× | 2×-0.2× | |
| Price / book | 1.5×+0.5× | 1×-0.6× | 0.9×-1.1× | 1.1×-0.7× | 1.4×-0.4× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Anika Therapeutics's ratios come from?
- Every ratio is computed from Anika Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
